EEF1D Antibody

Introduction to EEF1D Protein

EEF1D functions as a critical subunit of the eukaryotic translation elongation factor 1 (EEF1) complex, which serves as the enzymatic delivery system of aminoacyl tRNAs to ribosomes during protein synthesis. Beyond this canonical role, EEF1D acts as a guanine nucleotide exchange factor, facilitating the exchange of GDP bound to EF-1-alpha to GTP, thereby regenerating EF-1-alpha for subsequent rounds of aminoacyl-tRNA transfer to ribosomes .

The human EEF1D gene encodes multiple isoforms through alternative splicing, with distinct expression patterns. The longer isoform (647 amino acids) exhibits specific expression in brain and testis tissues, while shorter isoforms (252-281 amino acids) demonstrate ubiquitous expression throughout the body . This differential expression pattern suggests specialized functions in neural and reproductive tissues for the longer isoform.

Recent research has revealed that isoform 2 of EEF1D regulates the induction of heat-shock-responsive genes through association with heat shock transcription factors and direct DNA-binding at heat shock promoter elements (HSE) . This demonstrates the multifunctional nature of this protein beyond its well-established role in translation.

Characteristics of EEF1D Antibodies

EEF1D antibodies are immunoglobulins designed to specifically recognize and bind to the EEF1D protein or specific epitopes within it. These antibodies serve as essential reagents in numerous laboratory techniques that aid in detecting, quantifying, and studying the localization and function of EEF1D in biological systems.

Types and Sources of EEF1D Antibodies

Several commercial sources produce EEF1D antibodies with varying specifications to meet different research needs. The most common types are polyclonal antibodies raised in rabbits, though other varieties exist. Below is a comparative table of commercially available EEF1D antibodies:

Immunogen Information

The specificity of an antibody is largely determined by the immunogen used in its production. Different manufacturers utilize various approaches for generating EEF1D antibodies:

• Recombinant proteins encompassing sequences within the center region of human EEF1D

• Synthetic peptides derived from human EEF1D

• EEF1D fusion proteins

These different immunogen strategies may result in antibodies that recognize distinct epitopes within the EEF1D protein, potentially affecting their performance in specific applications.

Applications of EEF1D Antibodies in Research

EEF1D antibodies have been validated for multiple laboratory techniques, making them versatile tools for investigating this protein across various experimental contexts.

Western Blot Applications

Western blotting remains one of the most common applications for EEF1D antibodies, allowing researchers to detect and semi-quantify EEF1D protein in complex biological samples. Most commercial antibodies detect bands corresponding to EEF1D at approximately 31-40 kDa, though the observed molecular weight may vary due to post-translational modifications or alternative splicing .

Recommended working dilutions for Western blot applications typically range from 1:1000 to 1:50000, depending on the specific antibody and sample type . For optimal results, researchers should perform titration experiments to determine ideal concentrations for their specific conditions.

Immunohistochemistry and Immunocytochemistry

EEF1D antibodies enable the visualization of protein expression patterns in tissue sections (IHC) and cultured cells (ICC/IF). These techniques have revealed important insights about EEF1D distribution in normal and pathological tissues.

For immunohistochemistry applications, typical working dilutions range from 1:50 to 1:500 . Several antibodies have been validated for use in formalin-fixed, paraffin-embedded (FFPE) tissues, often requiring antigen retrieval with TE buffer (pH 9.0) or citrate buffer (pH 6.0) .

Immunoprecipitation and Co-Immunoprecipitation

Certain EEF1D antibodies have been validated for immunoprecipitation (IP) and co-immunoprecipitation (CoIP) applications, allowing researchers to isolate EEF1D protein complexes from cell or tissue lysates. These techniques have been instrumental in identifying novel protein interactions with EEF1D, providing insights into its functional networks .

For IP applications, recommended antibody amounts typically range from 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate .

EEF1D in Disease Pathology

Research using EEF1D antibodies has significantly contributed to our understanding of this protein's role in various pathological conditions.

EEF1D in Cancer Biology

Multiple studies have demonstrated overexpression of EEF1D in various cancers, including hepatocarcinomas, medulloblastomas, and gliomas . This overexpression suggests that EEF1D may play a crucial role in tumorigenesis and tumor progression.

A particularly significant study employed EEF1D antibodies to investigate the role of this protein in glioma . The researchers demonstrated that EEF1D promotes glioma cell proliferation, migration, and invasion through multiple mechanisms:

1. Regulation of the PI3K/Akt signaling pathway, a key regulator of malignant glioma cell growth and proliferation

2. Modulation of epithelial-mesenchymal transition (EMT), a process critical for cancer cell invasion

Knockdown of EEF1D significantly reduced cell proliferation and impaired EMT phenotypes, including cell invasion, suggesting potential therapeutic implications .

Autoantibodies Against EEF1D in Neurological Disorders

In a remarkable discovery, researchers identified autoantibodies against EEF1D in patients with cerebellar ataxia of unknown cause . These findings were confirmed through multiple techniques:

1. Tissue immunoprecipitation combined with mass spectrometric analysis identified EEF1D as the target antigen

2. Neutralization experiments, recombinant cell-based immunofluorescence assays, and Western blotting confirmed the specific binding of patient autoantibodies to EEF1D

The clinical manifestations in EEF1D-positive patients primarily included cerebellar syndrome, such as unsteady walking and limb ataxia . Immunotherapy proved effective in these patients, though cerebellar atrophy that occurred before treatment appeared irreversible . This research suggests that anti-EEF1D autoantibodies could serve as a biomarker for early diagnosis and treatment monitoring in a subset of autoimmune cerebellar ataxia cases.

Molecular Mechanisms of EEF1D Function

Advanced research utilizing EEF1D antibodies has elucidated several molecular mechanisms through which EEF1D exerts its biological functions beyond protein translation.

Signaling Pathway Regulation

EEF1D appears to modulate multiple signaling cascades that influence cell behavior. In glioma research, knockdown of EEF1D led to significant reductions in PI3K, phosphorylated PI3K, Akt, and phosphorylated Akt levels, indicating that EEF1D positively regulates the PI3K/Akt pathway . This pathway is crucial for controlling cell survival, proliferation, and metabolism, suggesting a mechanism by which EEF1D overexpression may contribute to tumorigenesis.

Epithelial-Mesenchymal Transition Modulation

EEF1D appears to play a significant role in regulating epithelial-mesenchymal transition (EMT), a process essential for embryonic development and wound healing but also implicated in cancer progression. Research in glioma cells revealed that EEF1D knockdown resulted in:

1. Increased expression of epithelial marker E-cadherin

2. Decreased expression of mesenchymal markers including N-cadherin and Snail

3. Reduced levels of β-catenin, a critical transcriptional factor in the EMT process

These findings suggest that EEF1D promotes a mesenchymal phenotype conducive to cancer cell invasion and metastasis.

Protein Interaction Network

Immunoprecipitation studies combined with mass spectrometry have identified numerous potential EEF1D-interacting partners, suggesting that EEF1D functions within a complex protein network . Functional enrichment analysis of these interactors revealed significant enrichment in processes related to nucleic acid metabolism and cell growth, indicating that EEF1D may influence DNA replication and RNA synthesis through interactions with catalytic proteins .

Future Directions in EEF1D Research

The multifaceted roles of EEF1D in normal cellular function and disease pathology suggest several promising avenues for future research.

Therapeutic Potential

Given its involvement in cancer progression, EEF1D represents a potential therapeutic target, particularly for aggressive malignancies like glioblastoma . Future research might focus on:

1. Developing small molecule inhibitors that specifically target EEF1D or its interactions

2. Exploring RNA interference strategies to downregulate EEF1D expression in cancer cells

3. Investigating combination therapies targeting EEF1D alongside established cancer treatments

Biomarker Development

The discovery of anti-EEF1D autoantibodies in cerebellar ataxia patients suggests potential diagnostic applications . Further research is needed to:

1. Determine the prevalence of these autoantibodies in larger patient cohorts

2. Assess their specificity and sensitivity as diagnostic biomarkers

3. Investigate their utility in monitoring treatment response and disease progression

Neurological Implications

The brain-specific expression of the long EEF1D isoform and the association of EEF1D mutations with neurodevelopmental disorders warrant deeper investigation . Future studies might explore:

1. The specific functions of brain-expressed EEF1D isoforms

2. The consequences of EEF1D dysfunction in various neurological conditions

3. The relationship between EEF1D, protein synthesis, and neuronal plasticity